Bolt Biotherapeutics Inc
BOLT
NASDAQ
Biotechnology
$3.35
USD
+0.14 (+4.36%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $6.18M
Volume 16.0K
Revenue
$4.70M
TTM
+12.8%
YoY
Gross Margin
100%
TTM
0.0%
YoY
Net Income
$-28.74M
TTM
+43.3%
YoY
Operating Cash Flow
$-31.45M
TTM
+38.8%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 1.8 | 2.2 | 2.5 | 0.0 | 0.0 |
YoY Growth | +41.5% | +90.1% | — | -97.9% | -99.7% |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 1.8 | 2.2 | 2.5 | 0.0 | 0.0 |
Selling, General & Administrative | 3.5 | 3.3 | 3.1 | 2.8 | 2.4 |
Other Operating Expenses | 0.0 | 0.0 | 1.5 | 0.0 | 0.8 |
Total Operating Expenses | 11.0 | 9.9 | 9.6 | 7.6 | 8.4 |
Operating Income | -9.2 | -7.7 | -7.1 | -7.6 | -8.4 |
EBITDA | -8.9 | -7.4 | -5.4 | -7.4 | -7.4 |
Other Income / Expense | 0.6 | 0.1 | 0.1 | 0.1 | 0.7 |
Total Other Income / Expense | 0.6 | 0.6 | 0.5 | 0.4 | 0.7 |
Income Before Income Taxes | -8.6 | -7.1 | -6.6 | -7.2 | -7.7 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -8.6 | -7.1 | -6.6 | -7.2 | -7.7 |
Consolidated Net Income / Loss | -8.6 | -7.1 | -6.6 | -7.2 | -7.7 |
Net Income Attributable to Common Shareholders | -8.6 | -7.1 | -6.6 | -7.2 | -7.7 |
Basic EPS | -$4.46 | -$3.72 | -$3.84 | -$4.31 | -$4.57 |
Diluted EPS | -$4.46 | -$3.72 | -$3.84 | -$4.31 | -$4.57 |
Basic Shares Outstanding | 1.9M | 1.9M | 1.7M | 1.7M | 1.7M |
Diluted Shares Outstanding | 1.9M | 1.9M | 1.7M | 1.7M | 1.7M |